Recombinant FNDC4 Protein, Human (ECD, Fc Tag)
Recombinant Proteins
The human FNDC4 (NP_073734.1) (Met1-Thr167) was expressed with the Fc region of mouse IgG1 at the C-terminus
The recombinant human FNDC4 consists 357a.a and predicts a molecular weight of 39.7 kDa.
Formulation:
The recombinant human FNDC4 consists 357a.a and predicts a molecular weight of 39.7 kDa.
Source:
HEK293 Cells
Usage:
Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Recombinant FNDC4 Protein, Human (ECD, Fc Tag)
Formulation: Recombinant FNDC4 Protein was lyophilized from sterile PBS, pH 7.4.1
Source: HEK293 Cells
| Product Name | Recombinant FNDC4 Protein, Human (ECD, Fc Tag) |
|---|---|
| Product Type | Recombinant Protein |
| Source | HEK293 Cells |
| Formulation | Recombinant FNDC4 Protein was lyophilized from sterile PBS, pH 7.4.1 |
| Molecular Weight | The recombinant human FNDC4 consists 357a.a and predicts a molecular weight of 39.7 kDa. |
| Endotoxin | < 1.0 EU per μg protein as determined by the LAL method |
| Purity | Greater than 85.4% as determined by SDS-PAGE. |
| Description | The human FNDC4 (NP_073734.1) (Met1-Thr167) was expressed with the Fc region of mouse IgG1 at the C-terminus |
| Host Species | Homo sapiens (Human) |
| Usage | Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use |
| Storage | Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| AA Sequence | Met1-Thr167 |
| Product Background | FNDC4 acts as an anti-inflammatory factor on macrophages and improves mouse model of induced colitis. FNDC4 could suppress osteoclast formation via NF-kappaB pathway and downregulation of CXCL1. Analysis of binding of FNDC4 to different immune cell types reveals strong and specific binding to macrophages and monocytes. FNDC4 treatment of bone marrow-derived macrophages in vitro results in reduced phagocytosis, increased cell survival and reduced proinflammatory chemokine expression. Hence, treatment with FNDC4 results in a state of dampened macrophage activity, while enhancing their survival. That FNDC4 may be a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases. |
| Memo | FRCP1 Protein, Human |
| Terminal | Asp 45 |
| Bioactivity | Please contact us for detailed information |